Jhunjhunwala-backed Concord Biotech IPO opens today: What do analysts say?

Concord Biotech IPO: The stock is commanding a 20 per cent premium in the grey market, as per ipowatch.com

Subscribe To Our Free Newsletter

All News, Business Standard All News